MDS/sAML BM samples
| No. . | Sex . | Age, y . | Diagnosis . | WHO 2016 . | Karyotype . | Molecular genetics (VAF %) . | IPSS . | IPSS-R . | Sample . |
|---|---|---|---|---|---|---|---|---|---|
| 1 | F | 62 | MDS | MDS-EB-1 | Complex | ASXL1 (40), TP53 (94) | INT-2 | High | MSCs |
| 2 | M | 77 | MDS | MDS-EB-2 | 46, XY, i(17) q(10) 47, idem, +8 | ASXL1 (50), TP53 deletion, FLT3-ITD | INT-2 | High | MSCs, CD34 |
| 3 | M | 67 | MDS | MDS-EB-1 | 46, XY.ish del(21)(q22q22)(3′RNX1+,5′RUNX1−) | IDH1 (20); ASXL1 (21); SRSF2 (30); STAG2 (58) | High | High | MSCs |
| 4 | M | 66 | sAML | AML-MRC | 46, XY, del(7)(q21q36); 46, XY, del(20)(q11q13) | U2AF1 (43) | N/A | N/A | MSCs, CD34 |
| 5 | M | 69 | MDS | MDS-EB-2 | 46, XY | ASXL1 (17) | INT-2 | High | MSCs, CD34 |
| 6 | M | 83 | MDS | MDS-EB-2 | Complex | Unk | High | Very high | MSCs |
| 7 | M | 83 | sAML | AML MRC | Complex | Unk | N/A | N/A | MSCs |
| 8 | M | 84 | sAML | AML-MRC | Complex | Unk | N/A | N/A | MSCs |
| 9 | M | 75 | sAML | AML-MRC | Complex | TP53 (27), U2AF1 (37) | N/A | N/A | MSCs, CD34 |
| 10 | F | 77 | MDS | MDS-EB-2 | 46, XX | Unk | INT-2 | High | MSCs |
| 11 | M | 56 | MDS | MDS-EB-2 | 46, XY | IDH2 (15) | INT-2 | High | MSCs |
| 12 | M | 72 | MDS | MDS-EB-1 | 47, XY, +8 | ASXL1 (45), EZH2 (27) | INT-1 | High | MSCs |
| 13 | F | 76 | MDS | MDS-MLD-RS | 46, XX | SF3B1 (40) | INT-1 | Low | MSCs |
| 14 | F | 60 | MDS | MDS-MLD | 46, XX | Unk | INT-1 | Low | MSCs |
| 15 | F | 60 | MDS | MDS-MLD | 46, XX | Unk | INT-1 | Low | MSCs |
| 16 | M | 71 | MDS | MDS-SLD | 46, XY | RUNX1 (10) | INT-1 | Low | MSCs |
| 17 | M | 82 | MDS | MDS-EB-1 | 46, XY | Unk | INT-1 | INT | MSCs |
| 18 | M | 82 | MDS | MDS-MLD | 46, XY | Unk | Low | Low | MSCs |
| 19 | M | 64 | sAML | AML-MRC | Complex | TP53 (40) | N/A | N/A | MSCs |
| 20 | M | 69 | MDS | MDS-EB-1 | 46, XY | ASXL1 (50), RUNX1 (50) | INT-1 | High | MSCs, CD34 |
| 21 | M | 41 | sAML | AML-MRC | Complex | Unk | N/A | N/A | MSCs |
| 22 | F | 86 | sAML | AML-MRC | 45, XX, −7 | NPM1 | N/A | N/A | MSCs |
| 23 | M | 66 | sAML | AML-MRC | 46, XY, del7q, del20q | U2AF1 (42), BCOR (43) | High | N/A | MSCs |
| 24 | M | 19 | sAML | AML-MRC | 46, XY | WT1 (33), MYC (31) | N/A | N/A | MSCs |
| 25 | M | 83 | MDS | MDS-EB-2 | 46, XY | Unk | INT-2 | High | MSCs |
| 26 | M | 75 | MDS | MDS-EB-2 | Complex | TP53 (27), U2AF1 (37) | High | Very high | MSCs |
| 27 | M | 76 | MDS | MDS-EB-2 | 46, XY | ASXL1 (50), RUNX1 (30) | INT-2 | High | CD34 |
| 28 | M | 65 | sAML | AML-MRC | Complex | Unk | N/A | N/A | CD34 |
| 29 | M | 54 | MDS | MDS-EB-2 | 46, XY | ASXL1 (27), RUNX1 (4), IDH2 (39) | INT-2 | INT | CD34 |
| 30 | F | 63 | sAML | AML-MRC | 46, XX | Unk | N/A | N/A | CD34 |
| 31 | M | 78 | MDS | MDS-MLD-RS | 46, XY | ASXL1 (43), SF3B1 (45), TET2 (43) | INT-1 | INT | CD34 |
| 32 | M | 68 | MDS | MDS-MLD-RS | 46, XY | SF3B1 (50), TET2 (50) | Low | Low | CD34 |
| 33 | W | 54 | MDS | MDS-MLD-RS | 47, XX, +19 | ASXL1 (5), SF3B1 (48) | INT-1 | Low | CD34 |
| 34 | W | 68 | MDS | MDS-EB-1 | 46, XX | SF3B1 (50), TET2 (50) | INT-1 | Low | CD34 |
| 35 | M | 61 | MDS | MDS-EB-2 | 46, XY | RUNX1 (40) | INT-2 | High | CD34 |
| 36 | M | 76 | sAML | AML-MRC | 46, XY, del(7q), 47, XY, +12 | TP53 | N/A | N/A | CD34 |
| 37 | M | 78 | MDS | MDS-MLD | 46, XY | SF3B1 (45) | Low | Low | CD34 |
| 38 | W | 77 | CMML | CMML-0 | 46, XX | TET2 (50), SRSF2 (30) | N/A | N/A | CD34 |
| No. . | Sex . | Age, y . | Diagnosis . | WHO 2016 . | Karyotype . | Molecular genetics (VAF %) . | IPSS . | IPSS-R . | Sample . |
|---|---|---|---|---|---|---|---|---|---|
| 1 | F | 62 | MDS | MDS-EB-1 | Complex | ASXL1 (40), TP53 (94) | INT-2 | High | MSCs |
| 2 | M | 77 | MDS | MDS-EB-2 | 46, XY, i(17) q(10) 47, idem, +8 | ASXL1 (50), TP53 deletion, FLT3-ITD | INT-2 | High | MSCs, CD34 |
| 3 | M | 67 | MDS | MDS-EB-1 | 46, XY.ish del(21)(q22q22)(3′RNX1+,5′RUNX1−) | IDH1 (20); ASXL1 (21); SRSF2 (30); STAG2 (58) | High | High | MSCs |
| 4 | M | 66 | sAML | AML-MRC | 46, XY, del(7)(q21q36); 46, XY, del(20)(q11q13) | U2AF1 (43) | N/A | N/A | MSCs, CD34 |
| 5 | M | 69 | MDS | MDS-EB-2 | 46, XY | ASXL1 (17) | INT-2 | High | MSCs, CD34 |
| 6 | M | 83 | MDS | MDS-EB-2 | Complex | Unk | High | Very high | MSCs |
| 7 | M | 83 | sAML | AML MRC | Complex | Unk | N/A | N/A | MSCs |
| 8 | M | 84 | sAML | AML-MRC | Complex | Unk | N/A | N/A | MSCs |
| 9 | M | 75 | sAML | AML-MRC | Complex | TP53 (27), U2AF1 (37) | N/A | N/A | MSCs, CD34 |
| 10 | F | 77 | MDS | MDS-EB-2 | 46, XX | Unk | INT-2 | High | MSCs |
| 11 | M | 56 | MDS | MDS-EB-2 | 46, XY | IDH2 (15) | INT-2 | High | MSCs |
| 12 | M | 72 | MDS | MDS-EB-1 | 47, XY, +8 | ASXL1 (45), EZH2 (27) | INT-1 | High | MSCs |
| 13 | F | 76 | MDS | MDS-MLD-RS | 46, XX | SF3B1 (40) | INT-1 | Low | MSCs |
| 14 | F | 60 | MDS | MDS-MLD | 46, XX | Unk | INT-1 | Low | MSCs |
| 15 | F | 60 | MDS | MDS-MLD | 46, XX | Unk | INT-1 | Low | MSCs |
| 16 | M | 71 | MDS | MDS-SLD | 46, XY | RUNX1 (10) | INT-1 | Low | MSCs |
| 17 | M | 82 | MDS | MDS-EB-1 | 46, XY | Unk | INT-1 | INT | MSCs |
| 18 | M | 82 | MDS | MDS-MLD | 46, XY | Unk | Low | Low | MSCs |
| 19 | M | 64 | sAML | AML-MRC | Complex | TP53 (40) | N/A | N/A | MSCs |
| 20 | M | 69 | MDS | MDS-EB-1 | 46, XY | ASXL1 (50), RUNX1 (50) | INT-1 | High | MSCs, CD34 |
| 21 | M | 41 | sAML | AML-MRC | Complex | Unk | N/A | N/A | MSCs |
| 22 | F | 86 | sAML | AML-MRC | 45, XX, −7 | NPM1 | N/A | N/A | MSCs |
| 23 | M | 66 | sAML | AML-MRC | 46, XY, del7q, del20q | U2AF1 (42), BCOR (43) | High | N/A | MSCs |
| 24 | M | 19 | sAML | AML-MRC | 46, XY | WT1 (33), MYC (31) | N/A | N/A | MSCs |
| 25 | M | 83 | MDS | MDS-EB-2 | 46, XY | Unk | INT-2 | High | MSCs |
| 26 | M | 75 | MDS | MDS-EB-2 | Complex | TP53 (27), U2AF1 (37) | High | Very high | MSCs |
| 27 | M | 76 | MDS | MDS-EB-2 | 46, XY | ASXL1 (50), RUNX1 (30) | INT-2 | High | CD34 |
| 28 | M | 65 | sAML | AML-MRC | Complex | Unk | N/A | N/A | CD34 |
| 29 | M | 54 | MDS | MDS-EB-2 | 46, XY | ASXL1 (27), RUNX1 (4), IDH2 (39) | INT-2 | INT | CD34 |
| 30 | F | 63 | sAML | AML-MRC | 46, XX | Unk | N/A | N/A | CD34 |
| 31 | M | 78 | MDS | MDS-MLD-RS | 46, XY | ASXL1 (43), SF3B1 (45), TET2 (43) | INT-1 | INT | CD34 |
| 32 | M | 68 | MDS | MDS-MLD-RS | 46, XY | SF3B1 (50), TET2 (50) | Low | Low | CD34 |
| 33 | W | 54 | MDS | MDS-MLD-RS | 47, XX, +19 | ASXL1 (5), SF3B1 (48) | INT-1 | Low | CD34 |
| 34 | W | 68 | MDS | MDS-EB-1 | 46, XX | SF3B1 (50), TET2 (50) | INT-1 | Low | CD34 |
| 35 | M | 61 | MDS | MDS-EB-2 | 46, XY | RUNX1 (40) | INT-2 | High | CD34 |
| 36 | M | 76 | sAML | AML-MRC | 46, XY, del(7q), 47, XY, +12 | TP53 | N/A | N/A | CD34 |
| 37 | M | 78 | MDS | MDS-MLD | 46, XY | SF3B1 (45) | Low | Low | CD34 |
| 38 | W | 77 | CMML | CMML-0 | 46, XX | TET2 (50), SRSF2 (30) | N/A | N/A | CD34 |
AML-MRC, AML with myelodysplasia-related changes; CMML, chronic myelomonocytic leukemia; FLT3-ITD, fms-like tyrosine kinase 3–internal tandem duplication; IPSS, International Prognostic Scoring System; MDS-EB, MDS–excess of blasts; MDS-MLD, MDS–multilineage dysplasia; MDS-MLD-RS, MDS–multilineage dysplasia–ring sideroblast; MDS-SLD, MDS–single-lineage dysplasia; N/A, not applicable; R-IPSS, Revised International Prognostic Scoring System; sAML, secondary AML; Sample, samples used for generation of MSCs or CD34+ HSPCs; Unk, unknown; VAF, variant allele frequency; WHO, World Health Organization.